Pfizer, BioNTech’s COVID-19 vaccine should be ready for approval by the end of the year: WSJ


FILE PHOTO: A small bottle labeled with a “Vaccine” sticker is held near a medical syringe in front of the words “Coronavirus COVID-19” displayed in this illustration taken on April 10, 2020. REUTERS / Dado Ruvic / Illustration / File Photo

(Reuters) – BioNTech SE and Pfizer Inc’s COVID-19 vaccine candidate should be ready to seek regulatory approval by the end of 2020, the Wall Street Journal reported Friday, citing the CEO of the German firm of biotechnology.

The experimental vaccine, which has shown promise against rapidly spreading respiratory disease in early-stage human tests, is set to advance to a large trial involving 30,000 healthy participants later this month, pending a regulatory sign. .

If it obtains marketing approval, companies are preparing to manufacture up to 100 million doses by the end of 2020 and an additional 1.2 billion doses by the end of 2021 on sites in Germany and the United States, Reuters reported last week.

Several hundred million doses could be produced even before approval, according to the WSJ report here

BioNTech and Pfizer did not immediately respond to Reuters’ request for comment.

Manojna Maddipatla reports in Bengaluru

Our standards:Principles of the Thomson Reuters Trust.


Please enter your comment!
Please enter your name here